Xdemvy (lifitegrast ophthalmic solution) is not currently approved in Europe, with no indication of a 2026 approval date based on available information.
When might Xdemvy be available in Europe?
There is no publicly announced timeline for the European Medicines Agency's (EMA) review or potential approval of Xdemvy. Regulatory approval processes can vary significantly in length.
What is Xdemvy used for?
Xdemvy is a prescription eye drop used to treat the signs and symptoms of dry eye disease [1]. It is believed to work by reducing inflammation associated with dry eye [1].
How does Xdemvy work?
Lifitegrast, the active ingredient in Xdemvy, is a lymphocyte function-associated antigen-1 (LFA-1) antagonist. By binding to LFA-1, it inhibits the interaction of LFA-1 with its cognate ligand, ICAM-1. ICAM-1 is often upregulated in the ocular surface of dry eye patients, and its interaction with LFA-1 is thought to contribute to the inflammatory cycle of dry eye disease [1].
Who makes Xdemvy?
Xdemvy is manufactured by Tarsus Pharmaceuticals, Inc. [2].
What is the regulatory status of Xdemvy in other regions?
In the United States, Xdemvy received approval from the Food and Drug Administration (FDA) in July 2023 [2].
What are the potential side effects of Xdemvy?
The most common side effect reported in clinical trials for Xdemvy was decreased visual acuity [1]. Other reported side effects included taste disturbances and eye irritation [1].
What are the alternatives to Xdemvy for dry eye disease?
Treatment options for dry eye disease are varied and depend on the underlying cause and severity. These can include artificial tears, prescription eye drops that increase tear production (like cyclosporine or lifitegrast itself, if approved), punctal plugs, and lifestyle modifications [3].
What is the patent status of Xdemvy?
Information regarding the specific patent landscape and expiry dates for Xdemvy can be found on specialized drug patent databases [4].
Sources:
1. https://www.xdemvy.com/
2. https://www.tarsusrx.com/news-releases/news-release-details/tarsus-pharmaceuticals-inc-announces-fda-approval-xdemvy-lifitegrast
3. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/dry-eye
4. https://drugpatentwatch.com/